Search Results - "Servat, C. Codony"

Carbodiimide-mediated cross-linking of RNA to nylon membranes improves the detection of siRNA, miRNA and piRNA by northern blot by Pall, Gurman Singh, Codony-Servat, Carles, Byrne, Jane, Ritchie, Leigh, Hamilton, Andrew

“…The northern blot, or RNA gel blot, is a widely used method for the discovery, validation and expression analysis of small regulatory RNA such as small…”
Get full text

1967PTriple MET/SRC/PIM inhibition in MET addicted tumors by Attili, I, Bonanno, L, Bracht, J P, Berenguer, J, Codony-Servat, C, Codony-Servat, J, Ito, M, Conte, P F, Cui, J J, Karachaliou, N, Rosell, R

“…Abstract Background MET addicted tumors are known to show very short response to single MET inhibition. In MET addicted cells, MET inhibition leads to…”
Get full text

1967P - Triple MET/SRC/PIM inhibition in MET addicted tumors by Attili, I., Bonanno, L., Bracht, J.P., Berenguer, J., Codony-Servat, C., Codony-Servat, J., Ito, M., Conte, P.F., Cui, J.J., Karachaliou, N., Rosell, R.

“…MET addicted tumors are known to show very short response to single MET inhibition. In MET addicted cells, MET inhibition leads to activation of proviral…”
Get full text

Triple MET/SRC/PIM inhibition in MET addicted tumors by Attili, I., Bonanno, L., Bracht, J.P., Berenguer, J., Codony-Servat, C., Codony-Servat, J., Ito, M., Conte, P.F., Cui, J.J., Karachaliou, N., Rosell, R.

Get full text

Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small cell cell lung cancer cell models by Codony-Servat, J., Codony-Servat, C., Viteri, S., Ito, M., Chaib, I., Bracht, J., Molina-Vila, M.A., Karachaliou, N., Rosell, R.

Get full text

35P - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small cell cell lung cancer cell models by Codony-Servat, J., Codony-Servat, C., Viteri, S., Ito, M., Chaib, I., Bracht, J., Molina-Vila, M.A., Karachaliou, N., Rosell, R.

“…The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib improves therapy for non-small cell lung cancer (NSCLC) patients who…”
Get full text

35PHsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small cell cell lung cancer cell models by Codony-Servat, J, Codony-Servat, C, Viteri, S, Ito, M, Chaib, I, Bracht, J, Molina-Vila, M A, Karachaliou, N, Rosell, R

“…Abstract Background The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib improves therapy for non-small cell lung cancer…”
Get full text

Differential expression profile of lung squamous cell carcinoma (LSCC) and druggable targets to be combined with necitumumab (N) by Verlicchi, A., Lazzari, C., Servat, C. Codony, Vila, M.A. Molina, Servat, J. Codony, Chaib, I., Serrano, J.L. Ramírez, Karachaliou, N., Dazzi, C., Rosell, R.

Get full text

Biomarker driven combinations for synthetic lethal approaches in KRAS mutant (KRASm) lung adenocarcinoma (LAC) by Lazzari, C., Verlicchi, A., Servat, C. Codony, Servat, J. Codony, Vila, M.A. Molina, Chaib, I., Serrano, J.L. Ramírez, Karachaliou, N., de Marinis, F., Rosell, R.

Get full text